Healthcare provider profile · identity verified

Mark Christopher Juretic, MD

Internal Medicine · SANTA BARBARA, CA · NPI 1689778029

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	435	167
Amlodipine Besylate	Amlodipine Besylate	207	71
Levothyroxine Sodium	Levothyroxine Sodium	201	68
Losartan Potassium	Losartan Potassium	195	74
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	150	31
Gabapentin	Gabapentin	147	33
Metformin Hcl	Metformin Hcl	125	48
Lisinopril	Lisinopril	120	50
Omeprazole	Omeprazole	104	42
Metoprolol Succinate	Metoprolol Succinate	92	35
Eliquis	Apixaban	91	20
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	90	34
Simvastatin	Simvastatin	82	25
Lorazepam	Lorazepam	80	39
Famotidine	Famotidine	69	25
Hydrochlorothiazide	Hydrochlorothiazide	69	27
Metoprolol Tartrate	Metoprolol Tartrate	68	27
Benazepril Hcl	Benazepril Hcl	65	20
Alprazolam	Alprazolam	61	19
Valsartan-Hydrochlorothiazide	Valsartan/Hydrochlorothiazide	61	20
Rosuvastatin Calcium	Rosuvastatin Calcium	60	30
Tamsulosin Hcl	Tamsulosin Hcl	57	18
Trazodone Hcl	Trazodone Hcl	57	28
Valsartan	Valsartan	56	22
Temazepam	Temazepam	54	suppressed
Sertraline Hcl	Sertraline Hcl	49	19
Escitalopram Oxalate	Escitalopram Oxalate	48	16
Pantoprazole Sodium	Pantoprazole Sodium	48	17
Allopurinol	Allopurinol	45	15
Furosemide	Furosemide	43	19
Jardiance	Empagliflozin	43	suppressed
Zolpidem Tartrate	Zolpidem Tartrate	41	17
Clopidogrel	Clopidogrel Bisulfate	39	11
Atenolol	Atenolol	38	11
Clonazepam	Clonazepam	36	suppressed
Meloxicam	Meloxicam	36	14
Lovastatin	Lovastatin	32	suppressed
Tramadol Hcl	Tramadol Hcl	32	13
Mounjaro	Tirzepatide	31	suppressed
Pioglitazone Hcl	Pioglitazone Hcl	31	suppressed
Doxazosin Mesylate	Doxazosin Mesylate	30	suppressed
Prednisone	Prednisone	28	suppressed
Fluoxetine Hcl	Fluoxetine Hcl	27	suppressed
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	27	suppressed
Alendronate Sodium	Alendronate Sodium	26	suppressed
Ezetimibe	Ezetimibe	26	13
Sumatriptan Succinate	Sumatriptan Succinate	26	suppressed
Carvedilol	Carvedilol	25	suppressed
Pravastatin Sodium	Pravastatin Sodium	25	suppressed
Felodipine Er	Felodipine	22	suppressed
Finasteride	Finasteride	22	suppressed
Fluticasone Propionate	Fluticasone Propionate	21	13
Fluticasone-Salmeterol	Fluticasone Propion/Salmeterol	21	suppressed
Premarin	Estrogens, Conjugated	19	suppressed
Spironolactone	Spironolactone	19	suppressed
Xarelto	Rivaroxaban	18	suppressed
Diclofenac Sodium	Diclofenac Sodium	17	suppressed
Duloxetine Hcl	Duloxetine Hcl	17	suppressed
Metformin Hcl Er	Metformin Hcl	17	suppressed
Solifenacin Succinate	Solifenacin Succinate	17	suppressed
Potassium Chloride	Potassium Chloride	16	suppressed
Citalopram Hbr	Citalopram Hydrobromide	15	suppressed
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	15	suppressed
Valacyclovir	Valacyclovir Hcl	15	suppressed
Glipizide	Glipizide	14	suppressed
Memantine Hcl	Memantine Hcl	14	suppressed
Ropinirole Hcl	Ropinirole Hcl	14	suppressed
Triamcinolone Acetonide	Triamcinolone Acetonide	14	suppressed
Celecoxib	Celecoxib	13	suppressed
Januvia	Sitagliptin Phosphate	13	suppressed
Oxycodone-Acetaminophen	Oxycodone Hcl/Acetaminophen	13	suppressed
Ozempic	Semaglutide	13	suppressed
Venlafaxine Hcl Er	Venlafaxine Hcl	13	suppressed
Diazepam	Diazepam	12	suppressed
Diltiazem 24hr Er	Diltiazem Hcl	12	suppressed
Synthroid	Levothyroxine Sodium	12	suppressed
Trulicity	Dulaglutide	12	suppressed
Advair Hfa	Fluticasone Propion/Salmeterol	11	suppressed
Amoxicillin	Amoxicillin	11	suppressed
Doxepin Hcl	Doxepin Hcl	11	suppressed
Fenofibrate	Fenofibrate Nanocrystallized	11	suppressed
Glipizide Er	Glipizide	11	suppressed
Montelukast Sodium	Montelukast Sodium	11	suppressed
Verapamil Er	Verapamil Hcl	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error